



**TTK Healthcare  
LIMITED**

TTKH:SECL:GJ:019:17

February 03, 2017

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

Company Code	:	3153
Scrip Code	:	507747

Dear Sirs,

**Re : Unaudited Financial Results for the Third Quarter ended 31<sup>st</sup> December, 2016**

We are forwarding herewith the Unaudited Financial Results for the Third Quarter ended 31<sup>st</sup> December, 2016, approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above document on record.

Thanking you

Yours faithfully  
**For TTK Healthcare Limited**

**(S KALYANARAMAN)**  
*Director & Wholetime Secretary*

Encl. : a/a



## TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

### PART I

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND 9 MONTHS ENDED 31st DECEMBER, 2016

(Rs. in lakhs)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for		Previous year ended
					Current Period ended	Previous period ended	
					(31/12/2016) Unaudited	(30/09/2016) Unaudited	
1.	Income from Operations						
	(a) Sales / Income from Operations (Inclusive of Excise Duty)	12288.59	13640.80	12686.19	41088.90	39541.42	51502.97
	(b) Other Operating Income	81.67	4.48	395.42	247.38	403.10	406.54
	<b>Total income from Operations</b>	<b>12370.26</b>	<b>13645.28</b>	<b>13081.61</b>	<b>41336.28</b>	<b>39944.52</b>	<b>51909.51</b>
2.	Expenses						
	(a) Cost of materials consumed	1140.27	1074.33	868.04	3393.34	2540.48	3570.28
	(b) Purchases of Stock-in-trade	4625.20	5366.45	4602.53	15433.34	14821.70	19525.48
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-153.05	-262.21	196.01	-247.85	326.60	-145.66
	(d) Employee benefits expense	2146.96	2160.10	2038.95	6586.81	6055.41	8141.85
	(e) Depreciation and amortisation expense	300.86	299.07	146.08	893.33	455.36	720.71
	(f) Marketing Expenses	1646.16	1968.44	1925.65	6197.18	6503.24	7685.67
	(g) Other expenses	2206.28	2331.61	2196.54	7032.64	6712.06	9084.92
	<b>Total Expenses</b>	<b>11912.68</b>	<b>12937.79</b>	<b>11973.80</b>	<b>39288.79</b>	<b>37414.85</b>	<b>48583.25</b>
3.	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and Exceptional Items (1-2)</b>	<b>457.58</b>	<b>707.49</b>	<b>1107.81</b>	<b>2047.49</b>	<b>2529.67</b>	<b>3326.26</b>
4.	Other Income	170.15	102.41	124.94	399.31	398.69	559.21
5.	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and Exceptional Items (3±4)</b>	<b>627.73</b>	<b>809.90</b>	<b>1232.75</b>	<b>2446.80</b>	<b>2928.36</b>	<b>3885.47</b>
6.	Finance Costs	69.63	79.90	71.09	251.55	218.59	332.73
7.	<b>Profit / (Loss) from Ordinary Activities after Finance Costs but before Exceptional Items (5±6)</b>	<b>558.10</b>	<b>730.00</b>	<b>1161.66</b>	<b>2195.25</b>	<b>2709.77</b>	<b>3552.74</b>
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9.	<b>Profit / (Loss) from Ordinary Activities before Tax (7±8)</b>	<b>558.10</b>	<b>730.00</b>	<b>1161.66</b>	<b>2195.25</b>	<b>2709.77</b>	<b>3552.74</b>
10.	Tax Expense	199.79	273.67	432.55	820.12	1037.52	1286.22
11.	<b>Net Profit / (Loss) from Ordinary Activities after Tax (9±10)</b>	<b>358.31</b>	<b>456.33</b>	<b>729.11</b>	<b>1375.13</b>	<b>1672.25</b>	<b>2266.52</b>
12.	Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13.	<b>Net Profit / (Loss) for the period (11±12)</b>	<b>358.31</b>	<b>456.33</b>	<b>729.11</b>	<b>1375.13</b>	<b>1672.25</b>	<b>2266.52</b>
14.	Share of Profit / (Loss) of Associates	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
15.	Minority Interest	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
16.	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13±14±15)</b>	<b>358.31</b>	<b>456.33</b>	<b>729.11</b>	<b>1375.13</b>	<b>1672.25</b>	<b>2266.52</b>
17.	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	776.60	776.60	776.60	776.60	776.60	776.60
18.	Reserve excluding Revaluation Reserves as per Balance Sheet of previous accounting year						12403.18
19.	<b>Earnings per share (before Extraordinary Items) (of Rs.10/- each) (not annualised):</b>						
	(a) Basic	4.61	5.88	9.39	17.71	21.53	29.19
	(b) Diluted	4.61	5.88	9.39	17.71	21.53	29.19
19.	<b>Earnings per share (after Extraordinary Items) (of Rs.10/- each) (not annualised):</b>						
	(a) Basic	4.61	5.88	9.39	17.71	21.53	29.19
	(b) Diluted	4.61	5.88	9.39	17.71	21.53	29.19

**NOTES:**

- (1) The above results have been reviewed by the Statutory Auditors and the Audit Committee of the Company and approved by the Board of Directors at their Meeting held on 3rd February, 2017, at Chennai.
- (2) The Other Operating Income for the Quarter ended 31st December, 2015 included non-recurring income of Rs.325 lakhs (Net) earned from product development trials conducted for a Third Party.
- (3) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (4) This Statement is also available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and also on the website of the Company ([www.ttkhealthcare.com](http://www.ttkhealthcare.com)).

For TTK HEALTHCARE LIMITED

  
T T RAGHUNATHAN  
EXECUTIVE VICE CHAIRMAN

Place: Chennai  
Date: February 03, 2017



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND 9 MONTHS ENDED 31st DECEMBER, 2016

(Rs. in lakhs)

Sl. No.	Particulars	3 months ended	Previous 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for		Previous Year ended
					Current period ended	Previous period ended	
					(31/12/2016) Unaudited	(31/12/2015) Unaudited	
<b>1.</b>	<b>Segment Revenue:</b>						
	(a) Pharmaceuticals	6345.18	7403.35	6706.41	21942.08	21423.42	27688.50
	(b) Medical Devices	579.78	614.87	496.73	1880.22	1671.51	2251.06
	(c) Consumer Products	3728.45	4149.87	3989.63	12331.89	12128.10	15406.46
	(d) Foods	1617.16	1458.31	1485.06	4874.66	4259.57	6069.32
	(e) Others	18.02	14.40	8.36	60.05	58.82	87.63
	<b>Total</b>	<b>12288.59</b>	<b>13640.80</b>	<b>12686.19</b>	<b>41088.90</b>	<b>39541.42</b>	<b>51502.97</b>
	Less : Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Net Sales / Income from Operations</b>	<b>12288.59</b>	<b>13640.80</b>	<b>12686.19</b>	<b>41088.90</b>	<b>39541.42</b>	<b>51502.97</b>
<b>2.</b>	<b>Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]</b>						
	(a) Pharmaceuticals	733.39	974.15	832.52	2697.32	2237.15	3117.82
	(b) Medical Devices	92.47	118.91	46.35	313.63	218.20	393.43
	(c) Consumer Products	28.71	133.17	74.33	217.24	156.54	115.64
	(d) Foods	-93.51	-196.54	462.01	-208.46	821.89	915.63
	(e) Others	6.33	3.60	4.12	21.57	25.77	31.89
	<b>Total</b>	<b>767.39</b>	<b>1033.29</b>	<b>1419.33</b>	<b>3041.30</b>	<b>3459.55</b>	<b>4574.41</b>
	Less : Finance Cost	69.63	79.90	71.09	251.55	218.59	332.73
	Less : Unallocable Expenses (Net of Unallocable Income)	139.66	223.39	186.58	594.50	531.19	688.94
	<b>Total Profit (+) / Loss (-) before tax</b>	<b>558.10</b>	<b>730.00</b>	<b>1161.66</b>	<b>2195.25</b>	<b>2709.77</b>	<b>3552.74</b>
<b>3.</b>	<b>Segment Assets</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>
		<b>31/12/2016</b>	<b>30/09/2016</b>	<b>31/12/2015</b>	<b>31/12/2016</b>	<b>31/12/2015</b>	<b>31/03/2016</b>
	(a) Pharmaceuticals	6742.54	6878.91	6944.55	6742.54	6944.55	6247.64
	(b) Medical Devices	2599.98	2652.60	2206.98	2599.98	2206.98	2303.13
	(c) Consumer Products	3086.78	3756.59	3568.88	3086.78	3568.88	3078.08
	(d) Foods	10509.04	10551.72	9848.92	10509.04	9848.92	10787.25
	(e) Others	76.83	72.81	66.56	76.83	66.56	81.39
		<b>23015.17</b>	<b>23912.63</b>	<b>22635.89</b>	<b>23015.17</b>	<b>22635.89</b>	<b>22497.49</b>
	Unallocated	12942.37	11379.88	11984.87	12942.37	11984.87	12276.90
	<b>Total Assets</b>	<b>35957.54</b>	<b>35292.51</b>	<b>34620.76</b>	<b>35957.54</b>	<b>34620.76</b>	<b>34774.39</b>
<b>4.</b>	<b>Segment Liabilities</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>
		<b>31/12/2016</b>	<b>30/09/2016</b>	<b>31/12/2015</b>	<b>31/12/2016</b>	<b>31/12/2015</b>	<b>31/03/2016</b>
	(a) Pharmaceuticals	6742.24	6888.84	6465.83	6742.24	6465.83	6332.31
	(b) Medical Devices	937.76	970.33	1020.65	937.76	1020.65	845.58
	(c) Consumer Products	3017.21	3767.84	3693.74	3017.21	3693.74	3458.32
	(d) Foods	1003.91	970.74	1302.70	1003.91	1302.70	1152.67
	(e) Others	128.31	121.26	113.32	128.31	113.32	120.47
		<b>11829.43</b>	<b>12719.01</b>	<b>12596.24</b>	<b>11829.43</b>	<b>12596.24</b>	<b>11909.35</b>
	Unallocated	6318.69	6147.69	5642.85	6318.69	5642.85	6055.09
	<b>Total Liabilities</b>	<b>18148.12</b>	<b>18866.70</b>	<b>18239.09</b>	<b>18148.12</b>	<b>18239.09</b>	<b>17964.44</b>

**NOTES:**

1. Segments have been identified in line with the Accounting Standard on Segment Reporting (AS-17) considering the organisation structure and the differential risks and returns of these segments.
2. Segment Sales is inclusive of Excise Duty related to the Sales of own manufactured goods for the current as well as for the previous periods.
3. Details of products included in each of the Segments are as below :
  - ❖ Pharmaceuticals include products for both Human and Veterinary use. It also includes OTC Brands like Woodward's Gripewater distributed by the Consumer Products Division.
  - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
  - ❖ Consumer Products comprise of marketing and distribution of EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc., (Own Brands) and also trading of Branded Condoms.
  - ❖ Foods comprise of manufacturing and marketing of Food Products.
  - ❖ "Others" include Printing and Publishing of Maps and Atlases.
4. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
5. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED



T T RAGHUNATHAN  
EXECUTIVE VICE CHAIRMAN

Place : Chennai

Date : February 03, 2017



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND 9 MONTHS ENDED 31st DECEMBER, 2016

(Rs. in lakhs)

Sl. No.	Particulars	Quarter ended	Corresponding 3 months ended in the previous year	Year to date figures for		Previous Year ended
				Current period ended	Previous period ended	
				(31/12/2016) Unaudited	(31/12/2015) Unaudited	
1.	Total income from Operations	12370.26	13081.61	41336.28	39944.52	51909.51
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	558.10	1161.66	2195.25	2709.77	3552.74
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	558.10	1161.66	2195.25	2709.77	3552.74
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	358.31	729.11	1375.13	1672.25	2266.52
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	N.A.	N.A.	N.A.	N.A.	N.A.
6.	Equity Share Capital (Face Value of Rs.10/- per share)	776.60	776.60	776.60	776.60	776.60
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year					12403.18
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)					
	(a) Basic	4.61	9.39	17.71	21.53	29.19
	(b) Diluted	4.61	9.39	17.71	21.53	29.19

### Notes:

- (1) The above is an extract of the detailed Statement of Unaudited Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The full financial results for the Quarter ended 31st December, 2016 are available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and also on the website of the Company ([www.ttkhealthcare.com](http://www.ttkhealthcare.com)).
- (3) These financial results have been reviewed by the Statutory Auditors and the Audit Committee of the Company and approved by the Board of Directors at their Meeting held on 3rd February, 2017.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN

EXECUTIVE VICE CHAIRMAN

Place: Chennai

Date: February 03, 2017